Nomura Reiterates Neutral Rating for Amgen (AMGN)
Amgen (NASDAQ:AMGN)‘s stock had its “neutral” rating restated by investment analysts at Nomura in a note issued to investors on Wednesday. They currently have a $142.00 price target on the stock, up from their previous price target of $129.00. Nomura’s price target would indicate a potential upside of 9.22% from the stock’s previous close.
Amgen (NASDAQ:AMGN) traded up 5.43% during mid-day trading on Wednesday, hitting $130.01. 8,472,513 shares of the company’s stock traded hands. Amgen has a 52-week low of $103.31 and a 52-week high of $128.96. The stock’s 50-day moving average is $119.1 and its 200-day moving average is $118.. The company has a market cap of $98.420 billion and a P/E ratio of 20.02.
Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 29th. The company reported $2.37 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.07 by $0.30. The company had revenue of $5.18 billion for the quarter, compared to the consensus estimate of $4.90 billion. During the same quarter in the prior year, the company posted $1.89 earnings per share. The company’s quarterly revenue was up 10.7% on a year-over-year basis. Analysts expect that Amgen will post $8.10 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, September 5th. Stockholders of record on Thursday, August 14th will be given a dividend of $0.61 per share. This represents a $2.44 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date of this dividend is Tuesday, August 12th.
A number of other analysts have also recently weighed in on AMGN. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of Amgen in a research note on Wednesday. They now have a $159.00 price target on the stock, up previously from $155.00. Separately, analysts at BMO Capital Markets raised their price target on shares of Amgen to $135.00 in a research note on Wednesday. Finally, analysts at RBC Capital raised their price target on shares of Amgen from $125.00 to $138.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. Five equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Amgen has a consensus rating of “Buy” and a consensus target price of $137.19.
Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.